Cipla Share Price Today (CIPLA)
TODAY IN ONE LINE
CIPLA fell 1.4% on average volume, in line with Nifty's -0.9% move.
With a market cap of ₹1.14 L Cr., it trades at a P/E of 29.83. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Cipla flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Consistent GrowthEPS compounded at 27.9% over 3 years
- ●High Capital EfficiencyROCE of 15.5% indicating pricing power
- ●Healthy Operating MarginsOPM is structurally strong at 20.9%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 54.6% YoY
- ●Sales ContractionQuarterly sales dropped 2.8% YoY
- ●Rising Receivables vs SalesReceivables grew 15.0% outpacing sales growth of 6.9%
Latest Cipla News
What changed recently?
Recent events, corporate actions, and announcements.
Cipla Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Cipla Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Cipla Ltd trades at a P/E of 29.83× and P/B of 3.36×, against the Healthcare sector median P/E of 40.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Cipla Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Cipla Ltd — derived from the live tape, not yesterday's close.
Cipla Ltd last traded at ₹1,412.7 with an intraday range of ₹1,395.7–₹1,423 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1412.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1479.83 | +67.13 | +4.75% |
| R3 | 1452.53 | +39.83 | +2.82% |
| R2 | 1437.77 | +25.07 | +1.77% |
| R1 | 1425.23 | +12.53 | +0.89% |
| PIVOT | 1410.47 | -2.23 | -0.16% |
| CURRENT | 1412.70 | — | — |
| S1 | 1397.93 | -14.77 | -1.05% |
| S2 | 1383.17 | -29.53 | -2.09% |
| S3 | 1370.63 | -42.07 | -2.98% |
| S4 | 1343.33 | -69.37 | -4.91% |
CIPLA is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹1395.7–₹1423
Trading Below opening range, showing Bearishness
Cipla Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Cipla Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Cipla Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.14 L Cr. and reported EPS of ₹48.01.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 27,548 | 28,163 ▲ 2.2% |
| Sales Growth YoY %Derived | 6.88% | 2.23% |
| Other Income | 862 | 882 ▲ 2.3% |
| Total Income | 28,409 | 29,045 ▲ 2.2% |
| 8,929 | 9,549 ▲ 6.9% | |
| Gross ProfitDerived | 18,619 | 18,613 ▼ 0.0% |
| Gross Margin %Derived | 67.59% | 66.09% |
| 11,491 | 12,731 ▲ 10.8% | |
| EBITDA (Operating Profit)Derived | 7,128 | 5,883 ▼ 17.5% |
| OPM %Derived | 25.87% | 20.89% |
| 1,169 | 989 ▼ 15.4% | |
| Profit Before Tax (PBT) | 6,821 | 5,224 ▼ 23.4% |
| 1,530 | 1,354 ▼ 11.5% | |
| Effective Tax %Derived | 22.43% | 25.92% |
| Total Profit for Period | 5,269 | 3,862 ▼ 26.7% |
| Less: Non-controlling Interests | -3 | -17 ▼ 426.8% |
| Net Profit (Owner's PAT)Derived | 5,273 | 3,879 ▼ 26.4% |
| Net Profit Margin %Derived | 19.14% | 13.77% |
| PAT Growth YoY %Derived | 27.93% | -26.43% |
| Earnings Per Share (EPS ₹) | 65.28 | 48.02 ▼ 26.4% |
| Diluted Shares Outstanding (Cr) | 81 | 81 ▲ 0.0% |
| Share of Profit from Associates/JVs | -22 | -8 ▲ 63.2% |
| Other Comprehensive Income (Net of Tax) | 219 | 688 ▲ 214.5% |
| Total Expenses (incl. D&A & Interest) | 21,589 | 23,821 ▲ 10.3% |
| Material Cost % of RevenueDerived | 19.64% | 20.74% |
| Employee Cost % of RevenueDerived | 17.54% | 19.05% |
| Other Cost % of RevenueDerived | 24.17% | 26.15% |
| Interest Coverage (x)Derived | 97.10x | 85.90x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 15,219 | 16,362 ▲ 7.5% | 17,132 ▲ 4.7% | 19,160 ▲ 11.8% | 21,763 ▲ 13.6% | 22,753 ▲ 4.5% | 25,774 ▲ 13.3% | 27,548 ▲ 6.9% | 28,163 ▲ 2.2% | |
| Sales Growth YoY %Derived | — | 7.51% | 4.70% | 11.84% | 13.59% | 4.55% | 13.28% | 6.88% | 2.23% | |
| Other Income | 358 | 477 ▲ 33.3% | 344 ▼ 27.8% | 266 ▼ 22.7% | 281 ▲ 5.6% | 475 ▲ 69.3% | 747 ▲ 57.0% | 862 ▲ 15.4% | 882 ▲ 2.3% | |
| Total Income | 15,577 | 16,839 ▲ 8.1% | 17,476 ▲ 3.8% | 19,426 ▲ 11.2% | 22,044 ▲ 13.5% | 23,229 ▲ 5.4% | 26,521 ▲ 14.2% | 28,409 ▲ 7.1% | 29,045 ▲ 2.2% | |
5,438 | 5,784 ▲ 6.4% | 5,991 ▲ 3.6% | 7,352 ▲ 22.7% | 8,496 ▲ 15.6% | 8,252 ▼ 2.9% | 8,820 ▲ 6.9% | 8,929 ▲ 1.2% | 9,549 ▲ 6.9% | ||
| Gross ProfitDerived | 9,781 | 10,578 ▲ 8.1% | 11,141 ▲ 5.3% | 11,808 ▲ 6.0% | 13,268 ▲ 12.4% | 14,501 ▲ 9.3% | 16,955 ▲ 16.9% | 18,619 ▲ 9.8% | 18,613 ▼ 0.0% | |
| Gross Margin %Derived | 64.27% | 64.65% | 65.03% | 61.63% | 60.96% | 63.73% | 65.78% | 67.59% | 66.09% | |
6,954 | 7,481 ▲ 7.6% | 7,935 ▲ 6.1% | 7,555 ▼ 4.8% | 8,715 ▲ 15.3% | 9,474 ▲ 8.7% | 10,663 ▲ 12.6% | 11,491 ▲ 7.8% | 12,731 ▲ 10.8% | ||
| EBITDA (Operating Profit)Derived | 2,826 | 3,097 ▲ 9.6% | 3,206 ▲ 3.5% | 4,252 ▲ 32.6% | 4,553 ▲ 7.1% | 5,027 ▲ 10.4% | 6,291 ▲ 25.1% | 7,128 ▲ 13.3% | 5,883 ▼ 17.5% | |
| OPM %Derived | 18.57% | 18.93% | 18.71% | 22.19% | 20.92% | 22.09% | 24.41% | 25.87% | 20.89% | |
1,360 | 1,495 ▲ 9.9% | 1,372 ▼ 8.2% | 1,228 ▼ 10.5% | 976 ▼ 20.5% | 1,099 ▲ 12.6% | 946 ▼ 13.9% | 1,169 ▲ 23.6% | 989 ▼ 15.4% | ||
| Profit Before Tax (PBT) | 1,669 | 2,079 ▲ 24.5% | 2,178 ▲ 4.8% | 3,290 ▲ 51.0% | 3,493 ▲ 6.2% | 4,038 ▲ 15.6% | 5,702 ▲ 41.2% | 6,821 ▲ 19.6% | 5,224 ▼ 23.4% | |
250 | 570 ▲ 127.7% | 631 ▲ 10.8% | 889 ▲ 40.8% | 934 ▲ 5.1% | 1,203 ▲ 28.8% | 1,547 ▲ 28.6% | 1,530 ▼ 1.1% | 1,354 ▼ 11.5% | ||
| Effective Tax %Derived | 14.98% | 27.39% | 28.98% | 27.01% | 26.73% | 29.79% | 27.12% | 22.43% | 25.92% | |
| Total Profit for Period | 1,417 | 1,492 ▲ 5.4% | 1,500 ▲ 0.5% | 2,389 ▲ 59.3% | 2,547 ▲ 6.6% | 2,833 ▲ 11.2% | 4,154 ▲ 46.6% | 5,269 ▲ 26.9% | 3,862 ▼ 26.7% | |
| Less: Non-controlling Interests | 6 | -35 ▼ 683.8% | -47 ▼ 33.3% | -16 ▲ 65.2% | 30 ▲ 282.8% | 31 ▲ 3.6% | 32 ▲ 3.8% | -3 ▼ 110.3% | -17 ▼ 426.8% | |
| Net Profit (Owner's PAT)Derived | 1,411 | 1,528 ▲ 8.3% | 1,547 ▲ 1.2% | 2,405 ▲ 55.5% | 2,517 ▲ 4.7% | 2,802 ▲ 11.3% | 4,122 ▲ 47.1% | 5,273 ▲ 27.9% | 3,879 ▼ 26.4% | |
| Net Profit Margin %Derived | 9.27% | 9.34% | 9.03% | 12.55% | 11.56% | 12.31% | 15.99% | 19.14% | 13.77% | |
| PAT Growth YoY %Derived | — | 8.31% | 1.23% | 55.50% | 4.65% | 11.33% | 47.10% | 27.93% | -26.43% | |
| Earnings Per Share (EPS ₹) | 17.52 | 18.96 ▲ 8.2% | 19.18 ▲ 1.2% | 29.82 ▲ 55.5% | 31.19 ▲ 4.6% | 34.71 ▲ 11.3% | 51.05 ▲ 47.1% | 65.28 ▲ 27.9% | 48.02 ▼ 26.4% | |
| Diluted Shares Outstanding (Cr) | 81 | 81 ▲ 0.1% | 81 ▲ 0.1% | 81 ▲ 0.0% | 81 ▲ 0.0% | 81 ▲ 0.0% | 81 ▲ 0.0% | 81 ▲ 0.0% | 81 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -3 | -17 ▼ 517.6% | -47 ▼ 176.4% | -13 ▲ 73.1% | -13 ▼ 0.2% | -3 ▲ 79.7% | -2 ▲ 38.8% | -22 ▼ 1274.2% | -8 ▲ 63.2% | |
| Other Comprehensive Income (Net of Tax) | 394 | -290 ▼ 173.7% | -129 ▲ 55.4% | 161 ▲ 224.8% | 384 ▲ 137.6% | 138 ▼ 64.1% | -121 ▼ 187.6% | 219 ▲ 281.3% | 688 ▲ 214.5% | |
| Total Expenses (incl. D&A & Interest) | 13,907 | 14,760 ▲ 6.1% | 15,298 ▲ 3.6% | 16,136 ▲ 5.5% | 18,551 ▲ 15.0% | 19,190 ▲ 3.4% | 20,819 ▲ 8.5% | 21,589 ▲ 3.7% | 23,821 ▲ 10.3% | |
| Material Cost % of RevenueDerived | 29.55% | 26.19% | 25.55% | 25.50% | 25.42% | 24.26% | 20.25% | 19.64% | 20.74% | |
| Employee Cost % of RevenueDerived | 17.68% | 17.46% | 17.67% | 16.97% | 16.22% | 16.83% | 16.72% | 17.54% | 19.05% | |
| Other Cost % of RevenueDerived | 28.02% | 28.26% | 28.65% | 22.46% | 23.82% | 24.80% | 24.65% | 24.17% | 26.15% | |
| Interest Coverage (x)Derived | 13.16x | 10.51x | 10.29x | 19.82x | 32.92x | 35.19x | 58.30x | 97.10x | 85.90x |
Cipla segment analysis : revenue and profit mix.
Disclosed business segments at Cipla with their share of revenue and profit, switchable between consolidated and standalone reporting.
Cipla discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Cipla Ltd.
Our AI distills the core fundamental drivers supporting Cipla Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Cipla Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
ROCE of 22.70% demonstrates superior capital efficiency versus peer benchmarks.
Operating margin of 17.49% reflects strong operational profitability and cost control.
Negative net debt of ₹101,348.7 Cr provides substantial financial flexibility and liquidity.
Low debt-to-equity ratio of 0.02 ensures fortress-like balance sheet strength.
Dividend yield of 1.11% offers attractive income generation for shareholders.
Key Risks.
Latest quarterly EPS declined 54.6% YoY despite revenue growth, signaling earnings deterioration.
TTM revenue growth of -2.1% YoY indicates market stagnation and competitive headwinds.
Capex CAGR of 37.56% over five years strains cash flow sustainability and reinvestment capacity.
Promoter holding declined from 33.61% to 29.20% over three years, raising governance concerns.
ROE of 11.60% lags peer benchmarks, limiting shareholder value creation relative to competitors.
Flip Conditions.
Valuation risk. a P/E above 39 (~1.0× the sector multiple of 40.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.45%.
Cipla Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Cipla Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Cipla Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Cipla Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Cipla Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Cipla Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Cipla Ltd stood at 56.3% of traded volume, against a 20-day average of 53.0%.
Cipla announcements: results, concalls, ratings, M&A.
Filings Cipla sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Cipla files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 172 documents below.
General Updates
Cipla Limited has informed the Exchange about USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Cipla Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Cipla Limited has informed the Exchange about ESG Rating.
Analysts/Institutional Investor Meet/Con. Call Updates
Cipla Limited has informed the Exchange about Schedule of meet
Updates
Cipla Limited has informed the Exchange regarding corrigendum to the intimation dated 3rd July, 2026 regarding 'Transcript of the 90th Annual General…
Investor decks & rating reports.
Cipla dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Cipla has declared, sequenced by announce and record date.
Cipla corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Cipla Ltd: business, sector, key facts.
What Cipla Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Cipla Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: CIPLA, BSE: 500087.
Cipla Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global presence spanning the United States, South Africa, and other international markets. Established in 1935, the company's core business revolves around the manufacturing, development, sale, and distribution of a diverse range of pharmaceutical products.
Cipla operates primarily through two segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment forms the cornerstone of its business, encompassing the production and marketing of both generic and branded generic medications. This extensive portfolio covers a wide spectrum of therapeutic areas, addressing critical health concerns across numerous disease categories.
The company's product offerings are remarkably broad, including formulations and active pharmaceutical ingredients (APIs) targeting conditions such as myocardial infarction (MI), angina, heart disease, pulmonary illnesses, kidney failure, Alzheimer's disease, hypertension, arrhythmias, lipid abnormalities and diabetes, obesity, central nervous system disorders, HIV/AIDS, respiratory ailments including asthma, urological issues, oncology, cardio-metabolic diseases, pediatric health concerns, infectious diseases, critical care situations, hepatitis, women's health problems, ophthalmological conditions, and neuropsychiatric disorders. This comprehensive approach allows Cipla to cater to a vast patient population globally.
Beyond its core pharmaceutical business, Cipla is actively involved in several strategic growth areas under its New Ventures segment. This includes expansion into the consumer healthcare market, the development and commercialization of biosimilars (biologically similar medications), and the pursuit of opportunities within the specialty pharmaceutical sector. This diversification strategy positions Cipla for continued growth and expansion into high-value markets.
In summary, Cipla's business model is built upon a foundation of manufacturing and distributing a wide array of generic and branded generic pharmaceuticals across a multitude of therapeutic areas. Their strategic diversification into consumer healthcare, biosimilars, and specialty pharmaceuticals underscores their commitment to innovation and long-term growth within the global healthcare landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Cipla Ltd (CIPLA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Cipla Ltd (CIPLA)?
The current share price of Cipla Ltd (CIPLA) is ₹1,412.7. Today, the stock has declined by ₹19.80 (1.38%), trading in a range of ₹1,395.7 to ₹1,423. The stock opened at ₹1,423 with a trading volume of 11,69,723 shares.
02Is Cipla Ltd stock a good investment for long-term?
Cipla Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,14,123.53 crores, P/E ratio of 29.83, ROE of 11.60%, and ROCE of 15.50%. The dividend yield stands at 0.90%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Cipla Ltd stock?
The 52-week high price of Cipla Ltd (CIPLA) is ₹1,673, while the 52-week low is ₹1,165.7. Currently trading at ₹1,412.7, the stock is 48.7% away from its 52-week low and 15.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Cipla Ltd stock at the current price?
Whether to buy Cipla Ltd stock at ₹1,412.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 29.83 and P/B ratio of 3.36. Today's performance shows a loss of 1.38%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Cipla Ltd and when is the next dividend?
Cipla Ltd offers a dividend yield of 0.90%, which means for every ₹100 invested at the current price of ₹1,412.7, you can expect to receive approximately ₹0.90 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Cipla Ltd?
Cipla Ltd's key financial metrics include: P/E Ratio: 29.83, P/B Ratio: 3.36, ROE: 11.60%, ROCE: 15.50%, Dividend Yield: 0.90%, EPS: ₹48.01, Book Value: ₹426.25, and Debt-to-Equity: 0.02. The company's market cap stands at ₹1,14,123.53 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Cipla Ltd stock performing today in the market?
Cipla Ltd stock opened at ₹1,423 and is currently trading at ₹1,412.7, showing a decline of ₹19.80 (1.38%). The intraday high is ₹1,423 and low is ₹1,395.7. The trading volume stands at 11,69,723 shares, indicating strong market participation today.
08What is the P/E ratio of Cipla Ltd and what does it indicate?
Cipla Ltd has a Price-to-Earnings (P/E) ratio of 29.83, which means investors are willing to pay ₹29.83 for every ₹1 of earnings. With an EPS of ₹48.01, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Cipla Ltd (CIPLA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.